atai Life Sciences Reports Third Quarter 2023 Financial

Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is...

Related Keywords

Berlin ,Germany , ,Nasdaq ,Exchange Commission ,American College Of Neuropsychopharmacology ,Demerx Ib Inc ,Hercules Capital Inc ,Life Sciences ,Development Rd Expenses ,Florian Brand ,Pipeline Highlights ,Pro Cognitive Neuromodulator ,Cognitive Impairment Associated ,Novel Oral Neuromodulator ,Enhances Synaptic Plasticity ,American College ,Treatment Resistant Depression ,Opioid Use Disorder ,Post Traumatic Stress Disorder ,Psilocybin Therapy ,Pivotal Trial ,Anorexia Nervosa ,Cash Equivalents ,Private Securities Litigation Reform Act ,Hercules Capital ,Annual Report ,Months Ended September ,Nasdaq Atai ,Tai Life Sciences Ag ,